8-K
Senti Biosciences Announces Board Resignation and CVR Distribution Record Date
8-K
Pro Forma Financials Reflect Divestiture of Operating Subsidiaries and Ongoing Rett Syndrome and TIL Programs After Merger
8-K
Senti Biosciences Holdings, Inc. Announces Voting Results from Reconvened 2026 Annual Meeting of Stockholders
8-K
Senti Biosciences Adjourns 2026 Annual Meeting of Stockholders to October 15, 2026
8-K
Brenda Cooperstone Resigns from Senti Biosciences Board of Directors
8-K
Senti Biosciences Secures $2.0 Million in Convertible Notes and $2.5 Million Equity Commitment
